Disseminated intravascular coagulation in acute leukemia

Area of Science:

• Hematology
• Oncology
• Pathophysiology

Background:

• Malignancy induces a hypercoagulable state, increasing risks of thrombosis and hemorrhage.
• Disseminated intravascular coagulation (DIC) and severe bleeding are common in acute leukemias, particularly acute promyelocytic leukemia (APL).
• Leukemic cell properties, chemotherapy, and infections exacerbate hemostatic abnormalities and bleeding risk.

Purpose of the Study:

• To describe coagulopathy in acute leukemia.
• To summarize hemostatic abnormalities and pathogenetic mechanisms.
• To review current management strategies for life-threatening bleeding, focusing on the impact of all-trans retinoic acid (ATRA) in APL.

Main Methods:

• Literature review and synthesis of current knowledge on leukemia-associated coagulopathy.
• Analysis of pathogenetic mechanisms involving leukemic cells and hemostatic systems.
• Evaluation of therapeutic tools and management recommendations, including ATRA's role.

Main Results:

• Acute leukemias present with profound hemostatic imbalance, affecting coagulation, fibrinolysis, and proteolysis.
• Leukemic cell interactions with hemostasis are key pathogenetic factors.
• ATRA has revolutionized APL treatment, significantly altering its natural history and bleeding complications.

Conclusions:

• Understanding the complex coagulopathy in acute leukemia is vital for effective patient management.
• Current therapeutic strategies aim to mitigate bleeding risks associated with leukemia and its treatment.
• ATRA represents a paradigm shift in managing APL and its associated bleeding syndromes.